Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma

Journal of Urology

Volumn 171, Issue 1, 2004, Pages 114-119

  Sievers, Elisabeth ^a   Albers, Peter ^a   Schmidt Wolf, Ingo G H ^a   Märten, Angela ^a,b,c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Department of Surgery ^*  (Germany)

Author keywords

Carcinoma, renal cell; Dendritic cells; Immunotherapy; Kidney; Telomerase

Indexed keywords

CYTOKINE; GAMMA INTERFERON; TELOMERASE; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0348109413     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000094803.60928.d7     Document Type: Article

References (20)

1. Motzer, R. J., Bander, N. H. and Nanus, D. M.: Renal-cell carcinoma. N Engl J Med, 335: 865, 1996
2. Motzer, R. J., Mazumdar, M., Bacik, J., Russo, P., Berg, W. J. and Metz, E. M.: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol, 18: 1928, 2000
3. Yagoda, A.: Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol, 7: 199, 1989
4. Van Den Eynde, B. J., Gaugler, B., Probst-Kepper, M., Michaux, L., Devuyst, O., Lorge, F. et al: A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med, 190: 1793, 1999
5. Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S. et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med, 343: 750, 2000
6. Höltl, L., Rieser, C., Papesh, C., Ramoner, R., Herold, M., Klocker, H. et al: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol, 161: 777, 1999
7. Marten, A., Renoth, S., Heinicke, T., Albers, P., Pauli, A., Mey, U. et al: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther, 14: 483, 2003
8. Marten, A., Flieger, D., Renoth, S., Weineck, S., Albers, P., Compes, M. et al: Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother, 51: 637, 2002
9. Steinman, R. M.: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 9: 271, 1991
10. Vonderheide, R. H., Hahn, W. C., Schultze, J. L. and Nadler, L. M.: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10: 673, 1999
11. Su, Z., Vieweg, J., Weizer, A. Z., Dahm, P., Yancey, D., Turaga, V. et al: Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res, 62: 5041, 2002
12. Nair, S. K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J. S. et al: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med, 6: 1011, 2000
13. Heiser, A., Maurice, M. A., Yancey, D. R., Coleman, D. M., Dahm, P. and Vieweg, J.: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res, 61: 3388, 2001
14. Marten, A., Schottker B., Ziske, C., Weineck, S., Buttgereit, P., Huhn, D. et al: Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9-protein. J Immunother, 23: 464, 2000
15. Marten, A., Greten, T., Ziske, C., Renoth, S., Schottker B., Buttgereit, P. et al: Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells. Cancer Immunol Immunother, 51: 25, 2002
16. Schmidt-Wolf, I. G., Negrin, R. S., Kiem, H. P., Blume, K. G. and Weissman, I. L.: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med, 174: 139, 1991
17. Kemmner, W., Schlag, P. and Brossmer, R.: A rapid and simple procedure for dissociation of tumor tissue from the human colon. J Cancer Res Clin Oncol, 113: 400, 1987
18. Blomberg, K., Granberg, C., Hemmila, I. and Lovgren, T.: Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence J Immunol Methods, 86: 225, 1986
19. Greten, T. F., Slansky, J. E., Kubota, R., Soldan, S. S., Jaffee, E. M., Leist, T. P. et al: Direct visualization of antigen-specific T cells: HTLV-1 Tax 11-19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci USA, 95: 7568, 1998
20. Wittig, B., Marten, A., Dorbic, T., Weineck, S., Min, H., Niemitz, S. et al: Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther, 12: 267, 2001